AstraZeneca Pharma India Limited has obtained CDSCO approval for an additional indication of Durvalumab Solution for Infusion (Imfinzi) in 120 mg/2.4 mL and 500 mg/10 mL formulations. The drug can now be used in combination with FLOT chemotherapy for treating adult patients with resectable gastric or gastroesophageal junction adenocarcinoma. This approval enables the company to market the drug for this new indication in India, subject to any remaining statutory approvals.
AstraZeneca Pharma India Receives CDSCO Approval for Durvalumab's Additional Cancer Indication
